(Reuters) - Novartis's recently acquired eyecare business Alcon is facing a U.S. government investigation into alleged healthcare fraud, the Swiss drugmaker said on Tuesday.
Alcon received a subpoena from the U.S. Department of Health and Human Services on September 23 requesting the production of documents relating to marketing practices, as well as the remuneration of healthcare providers.
The case involves the Alcon products Vigamox, Nevanac, Omnipred and Econopred, as well as surgical equipment.
NOVARTIS (NOVN.CH)revealed the case in a footnote to its third-quarter results and said Alcon was cooperating with the civil investigation.
(Reporting by Ben Hirschler. Editing by Jane Merriman)
Relacionados
- El Observatorio contra la Homofobia pide a Mas (CiU) que desautorice a Duran
- Ciudadanos de Villafranca defiende el nombramiento de Ángel García Calle como director del Observatorio de Empleo
- M.Hiraldo (CSIC) pide que observatorio de cambio global "no caiga en triunfalismos y cuente con los mejores"
- PCE extremeño abre expediente de expulsión a Ángel García Calle, nombrado director del Observatorio de Empleo
- El PCEx abre un expediente de expulsión a Ángel García Calle, nombrado director del Observatorio de Empleo del Sexpe